Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J 2nd, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Treon SP, et al. Among authors: sheehy p. J Clin Oncol. 2009 Aug 10;27(23):3830-5. doi: 10.1200/JCO.2008.20.4677. Epub 2009 Jun 8. J Clin Oncol. 2009. PMID: 19506160 Free PMC article. Clinical Trial.
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
Hunter ZR, Manning RJ, Hanzis C, Ciccarelli BT, Ioakimidis L, Patterson CJ, Lewicki MC, Tseng H, Gong P, Liu X, Zhou Y, Yang G, Sun J, Xu L, Sheehy P, Morra M, Treon SP. Hunter ZR, et al. Among authors: sheehy p. Haematologica. 2010 Mar;95(3):470-5. doi: 10.3324/haematol.2009.010348. Epub 2009 Nov 10. Haematologica. 2010. PMID: 19903677 Free PMC article.
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
Sun JY, Xu L, Tseng H, Ciccarelli B, Fulciniti M, Hunter ZR, Maghsoudi K, Hatjiharissi E, Zhou Y, Yang G, Zhu B, Liu X, Gong P, Ioakimidis L, Sheehy P, Patterson CJ, Munshi NC, O'Connor OA, Treon SP. Sun JY, et al. Among authors: sheehy p. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):152-6. doi: 10.3816/CLML.2011.n.036. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454220
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, Xu L, Hunter ZR, Tseng H, Manning RJ, Patterson CJ, Sheehy P, Turnbull B. Treon SP, et al. Among authors: sheehy p. Br J Haematol. 2011 Jul;154(2):223-8. doi: 10.1111/j.1365-2141.2011.08726.x. Epub 2011 May 12. Br J Haematol. 2011. PMID: 21564078 Free article.
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
Treon SP, Hanzis C, Manning RJ, Ioakimidis L, Patterson CJ, Hunter ZR, Sheehy P, Turnbull B. Treon SP, et al. Among authors: sheehy p. Br J Haematol. 2011 Aug;154(3):357-62. doi: 10.1111/j.1365-2141.2011.08750.x. Epub 2011 May 25. Br J Haematol. 2011. PMID: 21615385 Free article.
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration.
Treon SP, Tripsas CK, Ciccarelli BT, Manning RJ, Patterson CJ, Sheehy P, Hunter ZR. Treon SP, et al. Among authors: sheehy p. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):241-3. doi: 10.1016/j.clml.2013.02.016. Epub 2013 Mar 22. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23523274
100 results